آموزش وردپرس
خانه / علیرضا اولیایی منش

علیرضا اولیایی منش

مشخصات عمومي



  • نام: علیرضا                 نام خانوادگي: اولیایی منش
  • بالاترين مدرك و رشته تحصيلي:

كارشناس ارشد □      دكتري PhD *      دكتري تخصصي □           دكتري حرفه اي □

  • رشته تخصصي سیاستگذاری سلامت
  • مستندات: آخرين حكم كارگزيني
  • مرتبه دانشگاهي:

استاد□             دانشيار*                  استاديار □                 مربي □                  محقق □

طرح تحقیقی



رديف عنوان طرح تحقيقاتي سال تصويب سال پايان سمت اجرايي در طرح  فوق
ارزیابی فناوری سلامت درمان زخم پای دیابتی بااستفاده از لارو مگس شماره قرارداد 92 93 مجری
2 ارزیابی فناوری سلامت سیستم Magneto Encephalography  به شماره قرارداد 93 93 مجری
3 ارزیابی فناوری سلامت رادیوتراپی با هدایت تصویری IGRT 94 94 همکار

پایان نامه



رديف عنوان سال دفاع استاد راهنما استاد مشاور
تحلیل و تاثیر قانون هرفمندی یارانه ها بر عدالت… 1395 دکتر علیرضا اولیایی منش  
طراحی مدل بومی اولویت بندی ارزیابی فناوری سلامت در ایران 1394   دکتر علیرضا اولیایی منش
3 بررسی وضعیت و علل نابرابری جنسیتی در سلامت و تحلیل سیاستگذاری عدالت جنسیتی سلامت و سیاستهای سلامت ایران با استفاده از چارچوب Bardach 1394   دکتر علیرضا اولیایی منش

مقالات



 

رديف عنوان مقاله نام مجله سال انتشار

مقاله

نويسنده اول

(مسول )

نويسنده

دوم

 

نوع ايندكس مجله
A Stakeholder Involvement in HTA at National Level:a study from Iran International Journal of Technology Assessment in Health Care 2016 دکتر یزدی زاده، شاهمرادی دکتر مجدزاده ISI

pubmed

2 Gender equity in health: A secondary analysis of data in Iran. Med J Islam Repub Iran 2016  Masoumeh Hosseini  Alireza Olyaeemanesh pubmed
Contribution of Targeted Subsidies Law to the Equity in Healthcare Financing in Iran: Exploring the Challenges of Policy Process Electronic Physician 2016     pubmed
,  Prioritizing the determinants of social health inequality in Iran: A multiple attribute decision making analysis. Iran Red Crescent Medical Journal 2014     ISI

pubmed

Establishment of Clinical Policy Making in Iran Patient Safety & Quality Improvement 2014     pubmed
  • Med J Islam Repub Iran. 2016 Feb 23;30:336. eCollection 2016.
  • Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: A meta-analysis.
  • Olyaeemanesh A1, Rahmani M2, Goudarzi R3, Rahimdel A4.
  • Author information
  • 1Assistant Professor, National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran. arolyaee@gmail.com.
  • 2MSc Student in Health Technology Assessment at Health School Department of Yazd University of Medical Sciences, Iran. Rahmani.mahbobeh@yahoo.com.
  • 3Assistant Professor, PhD in Health Economics, Kerman University of Medical Sciences, Kerman, Iran. rgoudarzi@yahoo.com.
  • 4MD, Assistant Professor of Neurology, Shahid Sadooghi Hospital, Yazd University of Medical Science, Yazd, Iran. Rahimdel30142@yahoo.com.
  • Abstract
  • BACKGROUND:
  • Intravenous immunoglobulin (IVIG) is an established treatment of immune mediated demyelinating neuropathy including Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy. Recent trials suggest its efficacy in treating relapsing- remitting multiple sclerosis. IVIG exerts a number of effects, which may be beneficial in treating multiple sclerosis (MS): Reduction of inflammation, inhibition of macrophages, and promotion of remyelination. The aim of this study was to provide an overall assessment of the existing trials of safety and effectiveness of IVIG in relapsing- remitting MS compared to other drugs currently available for the treatment of disease activity in MS.
  • METHODS:
  • A systematic search strategy was applied to MEDLINE (PubMed and Ovid Medline (1990- Nov 2014)), Cochrane Library 2014, and Trip Database 2014, CRD. The reference lists from the identified trials, MS clinical handbooks and guidelines for the use of IVIG were studied. This article was conducted without language restrictions. Randomized controlled trials of IVIG in MS were selected. Sixteen double-blinded trails were randomly selected. Ten trials were excluded and we performed a meta-analysis on the six trials (537 participants) of IVIG in comparison to placebo. The methodological quality of the trials was assessed using Jadad checklist.
  • RESULTS:
  • The meta-analysis showed a significant beneficial effect on proportion of relapse-free patients (OR: 1.693; 95% CI-1.205-2.380), on the proportion of patients who improved (OR:2.977; 95% CI 1.769-5.010; p=0.0001) and deteriorated (OR:0.522; 95% CI0.330-0.827; p=0.006) between placebo and IVIG-treated patients. In addition, there was a reduction in the annual relapse rate in the IVIG group compared to placebo, which was statistically significant (SMD=-0.218; 95% CI-0.412 to -0.024; p=0.028). The results of the meta-analysis did not show significant differences between Expanded Disability Status Scale (EDSS) changes from baseline (SMD,-0.025; 95% CI,-0.211 to 0.161; p=0.860).
  • CONCLUSION:
  • IVIG can be considered as an alternative therapeutic option, second-line therapy or adjuvant therapy, considering its beneficial effects (high tolerance, need to be injected with longer intervals, etc.) for treating relapsing-remitting MS patients.
  • KEYWORDS:
  • Intravenous Immunoglobulin; Meta-analysis; Multiple sclerosis; Relapsing–remitting Multiple Sclerosis
  • PMID:
  • 27390706

PMCID:

  • Med J Islam Repub Iran. 2016; 30: 344.
  • Published online 2016 Mar 14.
  • PMCID: PMC4898835
  • Gender equity in health: A secondary analysis of data in Iran
  • Masoumeh Hosseini, 1 Alireza Olyaeemanesh, 2 Batoul Ahmadi,* 3 Saharnaz Nedjat, 4 Faranak Farzadi, 5 Mohammad Arab, 6 and Arash Rashidian 7
  • 1 PhD, Department of Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.oohay@6002_m_iniessoh
  • 2 PhD, Assistant Professor, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.liamg@eeaylora
  • 3 PhD, Assistant Professor, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: ri.ca.smut.anis@abidamha
  • 4 PhD, Professor, Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.liamg@tajdenzanrahas
  • 5 PhD, Associate Professor, Health Services Management Group of Health Metric Research Center, Iranian Institute for Health Sciences Research, ACECR, Women’s Health Scientific Group, Academy of Medical Sciences, Iran. Email: moc.oohay@idazrafkanaraf
  • 6 PhD, Professor, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: ri.ca.smut@ahombara
  • 7 PhD, Professor, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: ri.ca.smut@naidihsara
  • (Corresponding author) PhD, Assistant Professor, Department of Health Management and Economics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran. Email: ri.ca.smut.anis@abidamha
  • Author information ► Article notes ► Copyright and License information ►
  • Received 2015 Jul 6; Accepted 2015 Oct 26.
  • Copyright © 2016 Iran University of Medical Sciences
  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
  • Abstract
  • Background: Gender inequality harms the health of millions of women and girls in all over the world. This study aimed to identify the state of gender equity in the health sector of the Islamic Republic of Iran.
  • Methods: This study was based on the secondary analysis of the available data in four provinces. The research team held three sessions to select the appropriate indicators for measuring gender equity in Iran. Moreover, using the data of different sources, the indexes were evaluated by applying the brain storming method. To demonstrate the difference between females and males, the ratio of females to males was measured in each indicator. The confidence intervals were used to show significant differences in the gap between men and women. Educational indicators were analyzed using the appraisal framework of UNESCO and International Institute for Education Planning.
  • Results: Findings revealed gender equality in the indicators of education and under–five underweight in all the provinces. However, the indicator of information on the mild psychological diseases showed inequality in favor of males. Infants’ mortality, under-five mortality, crude death, drug abuse and smoking showed inequality in favor of females in all the four provinces. The incidence of tuberculosis, severe psychological diseases, and basic and supplementary insurance coverage was equal in all provinces except Tehran.
  • Conclusion: This study revealed gender inequality in many indicators among the provinces. Therefore, improving this condition requires policymaking, planning, and conducting appropriate strategies with proper gender approaches.
  • Keywords: Equity in Health, Gender Equality, Gender Equity in Health, Women’s Health
  • Med J Islam Repub Iran. 2016 Feb 16;30:329. eCollection 2016.
  • The health systems’ priority setting criteria for selecting health technologies: A systematic review of the current evidence.
  • Mobinizadeh M1, Raeissi P2, Nasiripour AA3, Olyaeemanesh A4, Tabibi SJ5.
  • Author information
  • 1PhD Candidate, Department of Health Services Management, Science and Research Branch, Islamic Azad University, Tehran, Iran. mobinreza@yahoo.com.
  • 2Associate Professor, Department of Health Services Management, School of Management and Medical Information Science, Iran University of Medical Sciences, Tehran, Iran. raeissi2009@yahoo.com.
  • 3Associate Professor, Department of Health Services Management, Science and Research Branch, Islamic Azad University, Tehran, Iran. nasiripour@srbiau.ac.ir.
  • 4Assistant Professor, National Institute for Health Research, Tehran University of Medical Sciences, Tehran, Iran. arolyaee@gmail.com.
  • 5Professor, Department of Health Services Management, Science and Research Branch, Islamic Azad University, Tehran, Iran. sjtabibi@yahoo.com.
  • Abstract
  • BACKGROUND:
  • In the recent years, using health technologies to diagnose and treat diseases has had a considerable and accelerated growth. The proper use of these technologies may considerably help in the diagnosis and treatment of different diseases. On the other hand, unlimited and unrestricted entry of these technologies may result in induced demand by service providers. The aim of this study was to determine the appropriate criteria used in health technologies priority-setting models in the world.
  • METHODS:
  • Using MESH and free text, we sought and retrieved the relevant articles from the most appropriate medical databases (the Cochrane Library, PubMed and Scopus) through three separate search strategies up to March 2015. The inclusion criteria were as follows: 1) Studies with specific criteria; 2) Articles written in English; 3) Those articles conducted in compliance with priority setting of health technologies. Data were analyzed qualitatively using a thematic synthesis technique.
  • RESULTS:
  • After screening the retrieved papers via PRISMA framework, from the 7,012 papers, 40 studies were included in the final phase. Criteria for selecting health technologies (in pre assessment and in the assessment phase) were categorized into six main themes: 1) Health outcomes; 2) Disease and target population; 3) Technology alternatives; 4) Economic aspects; 5) Evidence; 6) and other factors. “Health effects/benefits” had the maximum frequency in health outcomes (8 studies); “disease severity” had the maximum frequency in disease and target population (12 studies); “the number of alternatives” had the maximum frequency in alternatives (2 studies); “cost-effectiveness” had the maximum frequency in economic aspects (15 studies); “quality of evidence” had the maximum frequency in evidence (4 studies); and “issues concerning the health system” had the maximum frequency in other factors (10 studies).
  • CONCLUSION:
  • The results revealed an increase in the number of studies on health technologies priority setting around the world, and emphasized the necessity of application of a multi- criteria approach for appropriate decision making about healthcare technologies in the health systems.
  • KEYWORDS:
  • Health Systems; Health Technology; Health Technology Assessment; Priority Setting; Priority Setting Criteria
  • The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
  • Saeideh Jafari Andarian, 1 Alireza Olyaeemanesh,* 2 Seyed Alireza Hosseini, 3 Ali Akbari Sari, 4 Shahram Firoozbakhsh, 5 Mojtaba Nouhi Jadesi, 6 and Mohammadreza Mobinizadeh 7
  • 1 MSc Student, HTA, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.liamg@hedieas.aj
  • 2 Assistant Professor, National Institute of Health Research, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.oohay@eeaylora
  • 3 PhD, Office for Clinical Trials, Food and Drug Organization, Tehran, Iran. Email: moc.liamg@7azer.iniessoh
  • 4 Associate Professor, Department of Health Management and Economics, and Knowledge Utilization Research Center, Tehran University of Medical Sciences, Tehran, Iran. Email: ri.ca.smut@irasirabka
  • 5 Associate Professor, Department of Pulmonary Medicine, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.oohay@surifahs
  • 6 PhD Student in Health Economics, Department of Health Economics, School of Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran. Email: moc.liamg@ihuonabatjom
  • 7 Young Researchers and Elites Club, Science and Research Branch, Islamic Azad University, Tehran, Iran. Email: moc.oohay@azernibom
  • (Corresponding author) Assistant Professor, National Institute of Health Research, Tehran University of Medical Sciences, Tehran, Iran. Email: moc.oohay@eeaylora
  • Author information ► Article notes ► Copyright and License information ►
  • Received 2015 Sep 8; Accepted 2015 Nov 9.
  • Copyright © 2016 Iran University of Medical Sciences
  • This is an open-access article distributed under the terms of the Creative Commons Attribution NonCommercial 3.0 License (CC BY-NC 3.0), which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
  • Abstract
  • Background: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease, which reduces the lung function and causes respiratory symptoms over time, and it is primarily associated with shortness of breath, cough and sputum production. Roflumilast, which is a long-acting selective inhibitor, reduces the anti-inflammatory effect of the main symptoms of COPD. The aim of this study was to compare the clinical effectiveness of adding roflumilast to the current treatment regimen of patients with severe COPD.
  • Methods: To retrieve the marker studies, medical databases were searched up to February 2014. We included studies, which compared the clinical effectiveness and safety of roflumilast as concomitant to Long-acting ß2-agonist/Long-acting muscarinic antagonist (LABA/LAMA) regimen, in adult patients with severe COPD. The number of exacerbations, changes in the lung function FEV1, FEV1/FVC and quality of life were the major predefined outcomes. Meta-analysis of outcomes was performed by the RevMan software, with I2> 50%, representing considerable heterogeneity.
  • Results: Seven randomized controlled trials and two systematic reviews were included. In terms of safety, participants were likely to experience more side effects from roflumilast compared to placebo, particularly gastrointestinal effects (diarrhea, nausea, vomiting), headache and weight loss. There was no significant difference in the risk of cardiac complications or flu-like symptoms or upper respiratory tract infection in the two groups. In terms of effectiveness, only a small improvement was observed in SGRQ (St George’s Respiratory Questionnaire) index. Roflumilast reduced moderate to severe attacks, and caused significant improvements in the lung function regardless of the severity of the disease and the concurrent use of other standard COPD therapies.
  • Conclusion: Roflumilast anti-inflammatory therapy reduces the chronic bronchitis symptoms in patients with moderate to severe COPD, and it can be safely used with other drugs simultaneously.
  • Keywords: Roflumilast, COPD, Safety, Effectiveness